WO2012096646A1 - Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées - Google Patents

Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées Download PDF

Info

Publication number
WO2012096646A1
WO2012096646A1 PCT/US2011/020676 US2011020676W WO2012096646A1 WO 2012096646 A1 WO2012096646 A1 WO 2012096646A1 US 2011020676 W US2011020676 W US 2011020676W WO 2012096646 A1 WO2012096646 A1 WO 2012096646A1
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
hepatitis
rna
sample
oligotargeter
Prior art date
Application number
PCT/US2011/020676
Other languages
English (en)
Other versions
WO2012096646A9 (fr
Inventor
Hassan Mohamed EL-SAID AZZAZY EL-BADAWY
Sherif Mohamed SHAWKY ABDUO
Original Assignee
The American University In Cairo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The American University In Cairo filed Critical The American University In Cairo
Priority to PCT/US2011/020676 priority Critical patent/WO2012096646A1/fr
Priority to EP11855330.4A priority patent/EP2663649A4/fr
Priority to MYPI2013002624A priority patent/MY166402A/en
Publication of WO2012096646A1 publication Critical patent/WO2012096646A1/fr
Publication of WO2012096646A9 publication Critical patent/WO2012096646A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D

Definitions

  • the gold nanoparticles will have an average diameter ranging from 12 to 20 nm and be spherical, they may also range from 15- 1 8 nm in diameter.
  • the presence of HCV in a sample may be detected by a colorimetric change of a sample after contacting it with gold nanoparticles.
  • nanoparticles exhibit a red color and aggregated gold nanoparticles a blue color, where a blue color is indicative of the presence of HCV RNA in a sample that is complementary to the oligotargeter is conjugated to an FAM dye or other fluorescent dye or fluorophore whose emission can be quenched by gold nanoparticles; and the presence of HCV is detected by the emission of fluorescence.
  • AuNPs Gold Nanoparticles.
  • preservative or additive for a sample includes additives such as heparin or EDTA.
  • additives such as heparin or EDTA.
  • the term also includes other agents which prevent degradation of HCV RNA or permit HC V RNA to be easily recognized in the method of the invention. These include normal saline or commercially available preservatives such as the one found in PAX gene tubes.
  • '"extraction buffer refers to
  • the selected putative oligotargeter sequences were further modified using the BLAST program by sequence alignment of a selected sequence in the HCV database.
  • the following nine HCV-specific genotype-specific oligotargeter sequences were identified after careful selection for their HCV genotypic specificity by the inventors.
  • citrate buffer describes a buffer containing citrate used to prepare or suspend the colloidal gold nanoparticles (AuNPs).
  • -C 6 alcohol, an ether, or sodium diphenyl aminosulfonate may be used.
  • a preferred salt is trisodium citrate salt at a concentration of 30-50 mM or 1 -2 wt% (no specific pH).
  • Suitable buffers and methods for making and using colloidal gold are incorporated by reference to John Turkevich. Colloidal gold. Part I. Gold Bull. 1985; 18(3): 86-92; John Turkevich. Colloidal gold. Part II. Gold Bull.
  • gold nanoparticle refers to spherical gold nanoparticles.
  • kit refers to a composition of matter containing one or more ingredients necessary to practice the method of detecting HCV according to the invention.
  • the kit will contain gold nanoparticles and a polynucleotide that binds to hepatitis C virus RNA in separate containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une trousse pour un essai colorimétrique à base de nanoparticules d'or pour un ARN du virus de l'hépatite C qui détecte l'ARN du VHC non amplifié dans des échantillons cliniques à l'aide de AuNP non modifiées et de polynucléotides ciblant les oligonucléotides qui se lient à l'ARN du VHC. L'invention concerne un procédé de détection du virus de l'hépatite C comprenant la mise en contact d'un échantillon suspecté de contenir le virus de l'hépatite C avec un polynucléotide qui se lie à l'ARN du virus de l'hépatite C et des nanoparticules d'or, la détection de l'agrégation de nanoparticules et la détection du virus de l'hépatite C dans l'échantillon lorsque que les nanoparticules s'agrègent (la couleur de la solution devient bleue) en comparaison à un échantillon témoin ou négatif ne contenant pas le virus lorsque les nanoparticules ne s'agrègent pas (la couleur de la solution reste rouge).
PCT/US2011/020676 2011-01-10 2011-01-10 Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées WO2012096646A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/US2011/020676 WO2012096646A1 (fr) 2011-01-10 2011-01-10 Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées
EP11855330.4A EP2663649A4 (fr) 2011-01-10 2011-01-10 Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées
MYPI2013002624A MY166402A (en) 2011-01-10 2011-01-10 Direct detection of unamplified hepatitis c virus rna using unmodified gold nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/020676 WO2012096646A1 (fr) 2011-01-10 2011-01-10 Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées

Publications (2)

Publication Number Publication Date
WO2012096646A1 true WO2012096646A1 (fr) 2012-07-19
WO2012096646A9 WO2012096646A9 (fr) 2012-08-30

Family

ID=46507350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020676 WO2012096646A1 (fr) 2011-01-10 2011-01-10 Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées

Country Status (3)

Country Link
EP (1) EP2663649A4 (fr)
MY (1) MY166402A (fr)
WO (1) WO2012096646A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9419200B2 (en) 2014-03-31 2016-08-16 Brother Kogyo Kabushiki Kaisha Piezoelectric actuator and recording head
CN113151584A (zh) * 2021-01-11 2021-07-23 南通大学 一种SARS-CoV-2检测试剂盒及检测方法
CN115961060A (zh) * 2022-08-22 2023-04-14 中国海洋大学 基于纳米金的等温扩增检测结核分枝杆菌的引物探针组、试剂盒、方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
US20090111092A1 (en) * 2004-01-07 2009-04-30 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1002781C1 (nl) * 1996-04-03 1997-10-06 Amsterdam Support Diagnostics Isolatie en/of amplificatie van hepatitis-C-virus-(HCV) -nucleïnezuren uit monsters waarvan vermoed wordt dat zij HCV bevatten.
WO2009131661A2 (fr) * 2008-04-21 2009-10-29 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour inhiber spécifiquement le virus de l'hépatite c (vhc) au moyen d'arn bicaténaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
US20090111092A1 (en) * 2004-01-07 2009-04-30 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFIN ET AL.: "Size- and distance-dependent nanoparticle surface-energy transfer (NSET) method for selective sensing of hepatitis C virus RNA.", CHEM. EUR. J., vol. 15, no. 2, 2009, pages 342 - 351, XP055116087 *
See also references of EP2663649A4 *
SHAWKY ET AL.: "Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles.", CLINICAL BIOCHEMISTRY, vol. 43, no. 13-14, September 2010 (2010-09-01), pages 1163 - 1168, XP027248991 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9419200B2 (en) 2014-03-31 2016-08-16 Brother Kogyo Kabushiki Kaisha Piezoelectric actuator and recording head
CN113151584A (zh) * 2021-01-11 2021-07-23 南通大学 一种SARS-CoV-2检测试剂盒及检测方法
CN115961060A (zh) * 2022-08-22 2023-04-14 中国海洋大学 基于纳米金的等温扩增检测结核分枝杆菌的引物探针组、试剂盒、方法及应用

Also Published As

Publication number Publication date
WO2012096646A9 (fr) 2012-08-30
EP2663649A4 (fr) 2014-08-27
EP2663649A1 (fr) 2013-11-20
MY166402A (en) 2018-06-25

Similar Documents

Publication Publication Date Title
Shawky et al. Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles
MX2013008116A (es) Deteccion directa del arn no amplificado del virus de la hepatitis c al usar las nanoparticulas de oro no modificadas.
Mackay et al. Molecular assays for detection of human metapneumovirus
CN111549176B (zh) 用于检测SARS-CoV-2的LAMP引物组及试剂盒
US20140356859A1 (en) Detection of nucleic acids using unmodified gold nanoparticles
US11299771B2 (en) Enhanced DNA sensing via catalytic aggregation of gold nanoparticles by DNA hybridization chain reaction
CN107022651B (zh) 一种快速检测丙型肝炎病毒核酸的试剂盒及其检测方法
JP2021129591A (ja) 血液サンプルをプールする方法
Zhong et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR
Zhong et al. Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients
CN109182600B (zh) 一种同步检测乙型肝炎病毒、丙型肝炎病毒、人免疫缺陷病毒1型的荧光定量pcr试剂盒
WO2023279042A2 (fr) Compositions et procédés pour la détection de variants de coronavirus 2 à syndrome respiratoire aigu sévère
JP2006524052A (ja) 重症急性呼吸器症候群コロナウイルスを検出する試薬および方法
US9303292B2 (en) Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles
TWI377255B (en) Nucleic acid detection
JP4806150B2 (ja) 腫瘍細胞検出のための核酸プライマー及びプローブ
WO2012096646A1 (fr) Détection directe de l'arn non amplifié du virus de l'hépatite c à l'aide de nanoparticules d'or non modifiées
Jin Molecular methods for identification and genotyping of BK virus
Ibrahim et al. Molecular Detection of Occult Hepatitis B virus in plasma and urine of renal transplant patients in Khartoum state Sudan
Cook et al. Use of whole blood specimens for routine clinical quantitation of hepatitis C virus RNA does not increase assay sensitivity
Mohammed et al. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3
US7534588B2 (en) Methods, kits and polynucleotides for simultaneously diagnosing viruses
Ou et al. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method
CN110684862B (zh) 用于定量检测乙型肝炎病毒的微滴数字pcr试剂盒及检测方法
CN114214455A (zh) 乙肝病毒DNA快速定量引物探针及其CRISPR/Cas12b检测系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11855330

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1301003858

Country of ref document: TH

Ref document number: MX/A/2013/008116

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2011855330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011855330

Country of ref document: EP